Rossi Paolo, Lorenzo Giorgio Di, Formisano Rita, Buzzi M Gabriella
Headache Centre, INI Grottaferrata, Rome, Italy.
Headache. 2004 Jul-Aug;44(7):713-8. doi: 10.1111/j.1526-4610.2004.04132.x.
To document the relationship between the use of subcutaneous (SQ) sumatriptan (sum) and a change in frequency pattern of cluster headache (CH) in six patients. To discuss the clinical and pathophysiological implications of this observation in the context of available literature.
Treatment with SQ sum may cause an increase in attack frequency of CH but data from literature are scant and controversial.
Six CH sum-naïve patients (three episodic and three chronic according to the International Headache Society (IHS) criteria) are described.
All six patients had very fast relief from pain and accompanying symptoms from the drug but they developed an increase in attack frequency soon after using SQ sum. In all patients, the CH returned to its usual frequency within a few days after SQ sum was withdrawn or replaced with other drugs. Five patients were not taking any prophylactic treatment and SQ sum was the only drug prescribed to treat their headache.
Physicians should recognize the possibility that treatment of CH with SQ sum may be associated with an increased frequency of headache attacks.
记录6例患者皮下注射舒马曲坦(sum)与丛集性头痛(CH)发作频率模式变化之间的关系。在现有文献背景下讨论这一观察结果的临床和病理生理学意义。
皮下注射舒马曲坦治疗可能会导致丛集性头痛发作频率增加,但文献数据较少且存在争议。
描述了6例初用舒马曲坦的丛集性头痛患者(根据国际头痛协会(IHS)标准,3例发作性和3例慢性)。
所有6例患者用药后疼痛及伴随症状均迅速缓解,但使用皮下注射舒马曲坦后不久发作频率增加。所有患者在停用皮下注射舒马曲坦或换用其他药物后几天内,丛集性头痛恢复到其通常频率。5例患者未接受任何预防性治疗,皮下注射舒马曲坦是唯一用于治疗其头痛的药物。
医生应认识到皮下注射舒马曲坦治疗丛集性头痛可能与头痛发作频率增加有关。